CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells $1,173,157.62 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 19,582 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $12,468,589.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Friday, March 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $72.48, for a total value of $1,449,600.00.
• On Monday, March 11th, Samarth Kulkarni sold 9,802 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $78.26, for a total value of $767,104.52.
• On Tuesday, February 20th, Samarth Kulkarni sold 6,370 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $79.67, for a total value of $507,497.90.
• On Thursday, February 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00.
• On Monday, January 29th, Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.51, for a total value of $3,025,500.00.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $56.16 on Friday. The stock has a fifty day moving average price of $73.51 and a 200-day moving average price of $63.34. The company has a market cap of $4.77 billion, a price-to-earnings ratio of -28.65 and a beta of 1.76. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. The business’s revenue was up 3253.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.41) earnings per share. Research analysts predict that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors have recently modified their holdings of CRSP. CWM LLC lifted its position in shares of CRISPR Therapeutics by 80.7% during the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after acquiring an additional 260 shares during the period. Tradewinds Capital Management LLC raised its holdings in shares of CRISPR Therapeutics by 545.5% during the 3rd quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock worth $32,000 after buying an additional 600 shares in the last quarter. Blue Trust Inc. acquired a new position in shares of CRISPR Therapeutics during the 4th quarter worth $32,000. Headlands Technologies LLC acquired a new position in shares of CRISPR Therapeutics during the 3rd quarter worth $34,000. Finally, Bourgeon Capital Management LLC raised its holdings in shares of CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after buying an additional 500 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Barclays boosted their target price on CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a report on Thursday, February 22nd. Chardan Capital boosted their target price on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Finally, Mizuho boosted their price target on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $76.29.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.